SKYE
Skye Bioscience, Inc.NASDAQHealthcare$0.71+2.35%ClosedMarket Cap: $23.8M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.42
P/S
0.00
EV/EBITDA
0.00
DCF Value
$0.10
FCF Yield
-38688.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-143.6%
ROA
-197.5%
ROIC
-286.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-14.9M | $-14.4M | $-0.36 | — |
| FY 2025 | $0.00 | -Infinity% | $-58.2M | $-55.9M | $-1.41 | — |
| Q3 2025 | $0.00 | NaN% | $-13.3M | $-12.8M | $-0.32 | — |
| Q2 2025 | $0.00 | NaN% | $-18.2M | $-17.6M | $-0.44 | — |
| Q1 2025 | $0.00 | NaN% | $-11.8M | $-11.1M | $-0.28 | — |
| Q4 2024 | $0.00 | NaN% | $-10.7M | $-9.7M | $-0.24 | — |
| FY 2024 | $0.00 | NaN% | $-30.2M | $-26.6M | $-0.73 | — |
| Q3 2024 | $0.00 | NaN% | $-5.0M | $-3.9M | $-0.10 | — |
| Q2 2024 | $0.00 | NaN% | $-8.4M | $-7.9M | $-0.20 | — |
| Q1 2024 | $0.00 | NaN% | $-6.2M | $-5.0M | $-0.18 | — |
| Q4 2023 | $0.00 | NaN% | $-4.1M | $-4.4M | $-0.36 | — |
| FY 2023 | $0.00 | NaN% | $-34.7M | $-37.6M | $-5.37 | — |